Cargando…

P476: AN ORAL COMBINATION THERAPY OF OR-2100 AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA

Detalles Bibliográficos
Autores principales:	Kamachi, Kazuharu, Ureshino, Hiroshi, Kawasoe, Kazunori, Kidoguchi, Keisuke, Yamamoto, Yuta, Fukuda-Kurahashi, Yuki, Kurahashi, Yuki, Watanabe, Tatsuro, Kimura, Shinya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428934/ http://dx.doi.org/10.1097/01.HS9.0000968812.73633.b7

Ejemplares similares

Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia
por: Kamachi, Kazuharu, et al.
Publicado: (2023)

A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation
por: Kawasoe, Kazunori, et al.
Publicado: (2023)

Adult T‐cell leukemia‐lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism
por: Yoshida‐Sakai, Nao, et al.
Publicado: (2021)

P1233: TUMOR PREVENTION USING DNA DEMETHYLATING AGENTS ON VIRUS-DERIVED CARCINOGENESIS IN MICE.
por: Yamamoto, Yuta, et al.
Publicado: (2023)

Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL
por: Kurahashi, Yuki, et al.
Publicado: (2022)

P1236: REGULATION OF DNA AND HISTONE METHYLATION THROUGH METHIONINE METABOLISM IN ATL LEUKEMOGENESIS
por: Watanabe, Tatsuro, et al.
Publicado: (2023)

Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects
por: Ureshino, Hiroshi, et al.
Publicado: (2021)

P1301: BIOLOGICAL SIGNIFICANCE OF UCK2 IN HTLV-1-INFECTED CELLS IN ATL LEUKEMOGENESIS AND ACQUIRED RESISTANCE TO AZACITIDINE
por: Watanabe, T., et al.
Publicado: (2022)

Accelerated Phase of Atypical Chronic Myeloid Leukemia with Severe Disseminated Intravascular Coagulation at Initial Presentation
por: Fujita, Mai, et al.
Publicado: (2020)

Benefit of the Reduced Dose Combination of Azacitidine and Venetoclax in an Elderly Patient With Acute Myeloid Leukemia
por: Fujino, Keita, et al.
Publicado: (2023)

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
por: Kidoguchi, Keisuke, et al.
Publicado: (2021)

P654: ALLELIC POLYMORPHISMS OF KIRS AND HLAS PREDICT FAVORABLE ACHIEVEMENT OF TREATMENT-FREE REMISSION IN CML: RESULTS FROM THE POKSTIC TRIAL, MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY
por: Ureshino, Hiroshi, et al.
Publicado: (2023)

PB1862: VENETOCLAX AND AZACITIDINE THERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE RENAL IMPAIRMENT
por: Naka, Ryosuke, et al.
Publicado: (2023)

Diffuse Large B-cell Lymphoma Involving an Abundant Infiltration of T Follicular Helper Cells
por: Ishii, Keitaro, et al.
Publicado: (2022)

Combined venetoclax and alvocidib in acute myeloid leukemia
por: Bogenberger, James, et al.
Publicado: (2017)

Venetoclax-containing regimens in acute myeloid leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2021)

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
por: Griffioen, Mila S., et al.
Publicado: (2022)

SAT-476 Alemtuzumab Induced Graves Disease
por: Caputi, Rafael C, et al.
Publicado: (2020)

SAT476 A Case of Thyroid Hemiagenesis
por: Kachhadia, Palak, et al.
Publicado: (2023)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

476. Gilead Sciences’ Commitment to the COVID-19 Pandemic
por: Lee, EunYoung, et al.
Publicado: (2020)

Whole gut virome analysis of 476 Japanese revealed a link between phage and autoimmune disease
por: Tomofuji, Yoshihiko, et al.
Publicado: (2022)

Aplastic Anemia in a Patient with Cronkhite-Canada Syndrome
por: Kidoguchi, Keisuke, et al.
Publicado: (2021)

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia
por: Knight, Tristan, et al.
Publicado: (2019)

How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia
por: Maiti, Abhishek, et al.
Publicado: (2022)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
por: Brancati, Serena, et al.
Publicado: (2021)

Hymeglusin Enhances the Pro-Apoptotic Effects of Venetoclax in Acute Myeloid Leukemia
por: Zhou, Cheng, et al.
Publicado: (2022)

Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia
por: Ramdohr, Florian, et al.
Publicado: (2022)

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
por: De Gregori, Simona, et al.
Publicado: (2023)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia
por: Oyogoa, Emmanuella, et al.
Publicado: (2023)

Draft Genome Sequence of Xanthomonas sacchari Strain LMG 476
por: Pieretti, Isabelle, et al.
Publicado: (2015)

Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL‐rearranged complex karyotype acute myeloid leukemia
por: Edahiro, Taro, et al.
Publicado: (2022)

End-of-Life Care of Acute Myeloid Leukemia Compared with Aggressive lymphoma in Patients Who Are Eligible for Intensive Chemotherapy: An Observational Study in a Japanese Community Hospital
por: Kokaji, Masato, et al.
Publicado: (2023)

Primary Chest Wall MYC/BCL6 Double-hit Lymphoma with t(3;7)(q27;p12) and t(8;14)(q24;q32) Translocations
por: Kamachi, Kazuharu, et al.
Publicado: (2019)

Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias
por: Nishida, Yuki, et al.
Publicado: (2023)

Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
por: Waggoner, Matthew, et al.
Publicado: (2022)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
por: Samra, Bachar, et al.
Publicado: (2020)

Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms
por: Yuan, Fangfang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ekcbg75bplaq5p2p9pfjcrmh42